BIRCHBIOMED
BirchBioMed is a clinical-stage biomedical company focused on the clinical evaluation. It specializes in development and commercialization of anti-scarring drugs, autoimmune therapeutics and novel strategies for transplantation. The company was founded in 2015 and headquartered in King City, Ontario.
BIRCHBIOMED
Industry:
Biotechnology Health Care Medical Pharmaceutical Therapeutics
Founded:
2015-01-01
Address:
King City, Ontario, Canada
Country:
Canada
Website Url:
http://www.birchbiomed.ca
Total Employee:
1+
Status:
Active
Total Funding:
5.3 M USD
Technology used in webpage:
Amazon GoDaddy DNS AWS Global Accelerator GoDaddy Email
Similar Organizations
Sierra Biomedical
Sierra Biomedical is a pre-clinical biomedical services company.
Current Employees Featured
Susan Elliott Co-Founder & CMO @ BirchBioMed
Co-Founder & CMO
Mark Miller Co-Founder, Chairman & CEO @ BirchBioMed
Co-Founder, Chairman & CEO
2014-07-01
Ryan Hartwell Co-Founder @ BirchBioMed
Co-Founder
Founder
Investors List
National Institute for Health Research
National Institute for Health Research investment in Venture Round - BirchBioMed
entrepreneurship@UBC
entrepreneurship@UBC investment in Pre Seed Round - BirchBioMed
Key Employee Changes
| Date | New article |
|---|---|
| 2021-04-15 | BirchBioMed Welcomes Dr. Jonathan Bourne as New Chief Science Officer |
Official Site Inspections
http://www.birchbiomed.ca
- Host name: aec037177372cc6cd.awsglobalaccelerator.com
- IP address: 3.33.251.168
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "BirchBioMed"
About Us – BirchBioMed
BirchBioMed is a cutting-edge clinical-stage biopharmaceutical company headquartered in Canada. The company is dedicated to pioneering innovative treatments for organ fibrosis, …See details»
Our Mission – BirchBioMed
BirchBioMed is a clinical-stage biopharmaceutical company headquartered in Canada. We are dedicated to the development of innovative treatments for organ fibrosis, scarring, related skin …See details»
BirchBioMed - Crunchbase Company Profile & Funding
BirchBioMed is a clinical-stage biomedical company. New. Resources. Advanced Search. Start Free Trial . ... birchbiomed.ca ; 94,614; Highlights. obfuscated. Total Funding Amount . Unlock …See details»
BirchBioMed Inc. - LinkedIn
BirchBioMed Inc., a clinical-stage biomedical company focused on the clinical evaluation, development and commercialization of anti-scarring drugs, autoimmune therapeutics and …See details»
BirchBioMed Inc. - The Org
BirchBioMed Inc., a clinical-stage biomedical company focused on the clinical evaluation, development and commercialization of anti-scarring drugs, autoimmune therapeutics and …See details»
BirchBioMed, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore BirchBioMed, Inc. with its drug pipeline, therapeutic area, technology platform, 2 clinical trials, 2 news, Disease Domain:Endocrinology and Metabolic Disease, Immune System …See details»
BirchBioMed Stock Data, Filings, Earnings, News & Transcripts
BirchBioMed Company Profile Company profile. Employees. Incorporated. British Columbia, Canada. Location. Ontario, Canada. Fiscal year end. Dec 31. SEC CIK. 0001670747. Latest …See details»
BirchBioMed Receives Health Canada Green Light to Start the Last …
Oct 24, 2024 BirchBioMed, a leading biopharmaceutical company expert in the development of products for scarring and other fibrosis-related disorders, announced the authorization from …See details»
Mark Miller - Chairman & CEO - BirchBioMed Inc.
Chairman & CEO · Chairman/CEO of BirchBioMed Inc., a clinical stage biopharmaceutical company focused on developing treatments for scarring …See details»
BirchBioMed Receives Health Canada Green Light to Start the Last …
Contact Us Today. Find out how Nutrasource can help you commercialize your innovations. Contact Us. October 24, 2024. Guelph, October 24, 2024: BirchBioMed, a leading …See details»
Leadership – BirchBioMed
He is the co-founder of BirchBioMed, the co-founder and Board Chairman of The Carlisle Group, Inc., a full service marketing and publishing company, Board Chairman of Trivest-Global …See details»
BirchBioMed announces completion of clinical trial for ... - Newswire
Aug 26, 2016 BirchBioMed's license was granted through UBC's University Industry Liaison Office. BirchBioMed is the 86 th life science spin-off company from the university. Both UBC …See details»
BirchBioMed Welcomes Dr. Jonathan Bourne as New Chief
Apr 15, 2021 BirchBioMed, a University of British Columbia ... www.birchbiomed.ca. × Modal title. Organization Profile. BirchBioMed. Contact Cision. 866-245-2317 from 8 AM - 10 PM ET ...See details»
BirchBioMed Gains Health Canada Green Light for …
Oct 25, 2024 BirchBioMed Gains Health Canada Green Light for Groundbreaking Clinical Program of FS2 to Minimize Scarring from Burns ... BirchBioMed selected SGS Nutrasource …See details»
BirchBioMed - Overview, News & Similar companies - ZoomInfo
Jan 21, 2021 BirchBioMed, Inc. to Present at the 11th Annual LD Micro Main Event VANCOUVER, BC / ACCESSWIRE / November 29, 2018 / BirchBioMed Inc., a clinical-stage …See details»
BirchBioMed is cleared to begin first-of-its-kind phase II
Feb 16, 2018 /CNW/ - BirchBioMed Inc. a biomedical company focused on the commercialization, clinical evaluation and development of proprietary anti-scarring drugs,...See details»
University of British Columbia – BirchBioMed
As a University of British Columbia (“UBC”) spin-off, BirchBioMed took on the significant challenge of developing FS2 and AI-001 as major therapeutic agents to be made available to millions of …See details»
BirchBioMed Receives Health Canada Green Light to Start the Last …
BirchBioMed recently announced the authorization from Health Canada to conduct its Phase 2/3 randomized clinical trial of a naturally based compound, FS2, ... “In this process, BirchBioMed …See details»
BirchBioMed Inc. Announces Positive Topline Data from Phase
Jan 22, 2021 /CNW/ - BirchBioMed Inc., a clinical-stage immunology company focused on the prevention and reduction of immunological fibrotic conditions and defects in the...See details»
Establishing Canada’s first large-scale bioinnovation centre
3 days ago Connor.Burton@acoa-apeca.gc.ca. Lori Selig Acting Director of Communications Atlantic Canada Opportunities Agency 902-266-7477 lori.selig@acoa-apeca.gc.ca Dr. Beth …See details»